do Rêgo Lima Luciana Vieira, Santos Ramos Patrícia Karla, Campos Marliane Batista, dos Santos Thiago Vasconcelos, de Castro Gomes Claudia Maria, Laurenti Márcia Dalastra, Corbett Carlos Eduardo Pereira, Silveira Fernando Tobias
Pathog Glob Health. 2014 Dec;108(8):381-4. doi: 10.1179/2047773214Y.0000000166. Epub 2014 Dec 9.
American visceral leishmaniasis (AVL) is an infectious disease, often with long-duration evolution, caused by Leishmania (L.) infantum chagasi. However, although the disease is considered the major clinical manifestation of the link between L. (L.) i. chagasi and the human immune response, we have recently identified five clinical-immunological profiles of infection in the Brazilian Amazon: three asymptomatic (Asymptomatic Infection--AI, Sub-clinical Resistant Infection--SRI, and Indeterminate Initial Infection--III), and two symptomatic ones [Symptomatic Infection--SI (=AVL) and Sub-clinical Oligosymptomatic Infection--SOI]. We confirm here the preclinical diagnosis of AVL through the IgM-antibody response in a case of an early infection (profile III) that evolved to the full disease after 6 weeks.
美洲内脏利什曼病(AVL)是一种由婴儿利什曼原虫恰加斯亚种(Leishmania (L.) infantum chagasi)引起的传染病,病程通常较长。然而,尽管该疾病被认为是婴儿利什曼原虫恰加斯亚种与人类免疫反应之间联系的主要临床表现,但我们最近在巴西亚马逊地区确定了感染的五种临床免疫特征:三种无症状(无症状感染——AI、亚临床抗性感染——SRI和初始不确定感染——III),以及两种有症状的(有症状感染——SI[=AVL]和亚临床轻度症状感染——SOI)。在此,我们通过对一例早期感染(特征III)的IgM抗体反应证实了AVL的临床前诊断,该病例在6周后发展为完全疾病。